AxoGen (AXGN) Competitors $13.95 -0.05 (-0.36%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends AXGN vs. ZYXI, BLFS, NTUS, CUTR, IRTC, ENOV, TNDM, CNMD, RXST, and SLNOShould you be buying AxoGen stock or one of its competitors? The main competitors of AxoGen include Zynex (ZYXI), BioLife Solutions (BLFS), Natus Medical (NTUS), Cutera (CUTR), iRhythm Technologies (IRTC), Enovis (ENOV), Tandem Diabetes Care (TNDM), CONMED (CNMD), RxSight (RXST), and Soleno Therapeutics (SLNO). AxoGen vs. Zynex BioLife Solutions Natus Medical Cutera iRhythm Technologies Enovis Tandem Diabetes Care CONMED RxSight Soleno Therapeutics Zynex (NASDAQ:ZYXI) and AxoGen (NASDAQ:AXGN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, community ranking, valuation, analyst recommendations, media sentiment, risk, earnings and profitability. Do insiders & institutionals have more ownership in ZYXI or AXGN? 29.7% of Zynex shares are held by institutional investors. Comparatively, 80.3% of AxoGen shares are held by institutional investors. 52.1% of Zynex shares are held by company insiders. Comparatively, 7.0% of AxoGen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Do analysts prefer ZYXI or AXGN? Zynex presently has a consensus target price of $14.00, suggesting a potential upside of 59.82%. AxoGen has a consensus target price of $15.00, suggesting a potential upside of 7.53%. Given Zynex's higher possible upside, analysts plainly believe Zynex is more favorable than AxoGen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zynex 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00AxoGen 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community prefer ZYXI or AXGN? AxoGen received 425 more outperform votes than Zynex when rated by MarketBeat users. Likewise, 72.71% of users gave AxoGen an outperform vote while only 57.14% of users gave Zynex an outperform vote. CompanyUnderperformOutperformZynexOutperform Votes2857.14% Underperform Votes2142.86% AxoGenOutperform Votes45372.71% Underperform Votes17027.29% Which has more risk and volatility, ZYXI or AXGN? Zynex has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500. Comparatively, AxoGen has a beta of 1.13, indicating that its stock price is 13% more volatile than the S&P 500. Which has stronger valuation & earnings, ZYXI or AXGN? Zynex has higher revenue and earnings than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than Zynex, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZynex$184.32M1.51$9.73M$0.1558.40AxoGen$159.01M3.85-$21.72M-$0.38-36.71 Does the media favor ZYXI or AXGN? In the previous week, Zynex had 6 more articles in the media than AxoGen. MarketBeat recorded 8 mentions for Zynex and 2 mentions for AxoGen. AxoGen's average media sentiment score of 0.56 beat Zynex's score of 0.10 indicating that AxoGen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zynex 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral AxoGen 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is ZYXI or AXGN more profitable? Zynex has a net margin of 2.49% compared to AxoGen's net margin of -9.53%. Zynex's return on equity of 13.05% beat AxoGen's return on equity.Company Net Margins Return on Equity Return on Assets Zynex2.49% 13.05% 3.78% AxoGen -9.53%-17.30%-8.63% SummaryZynex beats AxoGen on 10 of the 17 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get AxoGen News Delivered to You Automatically Sign up to receive the latest news and ratings for AXGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AXGN vs. The Competition Export to ExcelMetricAxoGenElectromedical equipment IndustryMedical SectorNASDAQ ExchangeMarket Cap$611.43M$3.56B$5.39B$8.53BDividend YieldN/A1.61%5.13%4.14%P/E Ratio-36.7116.11113.8115.12Price / Sales3.8557.221,483.2593.03Price / CashN/A46.0939.6434.05Price / Book6.283.504.665.02Net Income-$21.72M$89.83M$119.06M$225.46M7 Day Performance4.81%1.00%0.79%0.37%1 Month Performance-1.34%14.23%5.65%3.57%1 Year Performance267.11%17.99%36.76%29.42% AxoGen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AXGNAxoGen1.0629 of 5 stars$13.95-0.4%$15.00+7.5%+286.4%$611.43M$159.01M-36.71426Upcoming EarningsZYXIZynex3.7459 of 5 stars$8.88-2.6%$14.00+57.7%-1.5%$282.83M$184.32M59.201,100BLFSBioLife Solutions1.3246 of 5 stars$22.86+3.8%$26.67+16.7%+135.3%$1.05B$139.96M-13.53409News CoverageNTUSNatus MedicalN/A$32.96flatN/A+0.0%$1.14B$473.44M89.081,400CUTRCutera2.1469 of 5 stars$0.67+4.7%$5.33+698.4%-80.3%$13.43M$169.19M-0.10430Upcoming EarningsShort Interest ↓News CoverageIRTCiRhythm Technologies3.0679 of 5 stars$76.30+0.8%$113.90+49.3%-4.9%$2.37B$537.09M-17.872,000Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageENOVEnovis2.955 of 5 stars$41.17+3.0%$67.00+62.7%-5.8%$2.26B$1.91B-24.806,550Upcoming EarningsTNDMTandem Diabetes Care4.5349 of 5 stars$32.75+4.5%$55.13+68.3%+79.8%$2.14B$747.72M-15.672,400Upcoming EarningsPositive NewsCNMDCONMED4.8097 of 5 stars$63.75+2.6%$79.80+25.2%-28.7%$1.96B$1.28B20.304,000Earnings ReportAnalyst ForecastNews CoverageRXSTRxSight2.7696 of 5 stars$50.25-0.3%$60.14+19.7%+129.1%$1.86B$89.08M-49.26220Upcoming EarningsAnalyst ForecastInsider SellingNews CoverageSLNOSoleno Therapeutics4.2995 of 5 stars$55.31+0.7%$69.86+26.3%+132.7%$1.85BN/A-22.6730Upcoming Earnings Related Companies and Tools Related Companies ZYXI Alternatives BLFS Alternatives NTUS Alternatives CUTR Alternatives IRTC Alternatives ENOV Alternatives TNDM Alternatives CNMD Alternatives RXST Alternatives SLNO Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AXGN) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredNothing can stop this gold rallyAfter what's felt like nearly a decade of disappointing gains, gold is stronger than ever and continues to hit...Stansberry Research | SponsoredWall St. Legend: Millions of Americans About to Fall Out of the 1%Wall Street insider reveals the financial tidal wave about to knock millions of Americans out of the One Perce...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AxoGen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AxoGen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
